The SA Journal Diabetes & Vascular Disease Vol 12 No 2 (December 2015)

19 / 48

SA JOURNAL OF DIABETES & VASCULAR DISEASE REVIEW
VOLUME 12 NUMBER 2 • NOVEMBER 2015 61
110. Fitzpatrick AL, Kronmal RA, Gardner JP, et al . Leukocyte telomere length and
cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol 2007;
165: 14–21.
111. Farzaneh-Far R, Cawthon R, Na B, et al. Prognostic value of leucocyte telomere
length in patients with stable coronary artery disease. Data from the Heart and
Soul Study. Arterioscler Thromb Vasc Biol 2008; 28: 1379–1384.
112. Zee RYL, Michaud SE, Germer S, Ridker PM. Association of shorter mean telomere
length with risk of incident myocardial infarction: A prospective, nested case-
control approach. Clin Chim Acta 2009; 403: 139–141.
113. Ligi P. Diet, nutrition and telomere length. J Nutr Biochem 2011; 22: 895–901.
114. Zhu H, Belcher M, van der Harst P. Healthy aging and disease: role for telomere
biology? Clin Sci 2011; 120: 427–440.
115. La Rocca TJ, Seals DR, Pierce GL. Leukocyte telomere length is preserved with
aging in endurance exercise-trained adults and related to maximal aerobic
capacity. Mechan Ageing Develop 2010; 131: 165–167.
116. Tarkanyi I, Aradi J. Pharmacological intervention strategies for affecting telomerase
activity : Future prospects to treat cancer and degenerative disease. Biochimie
2008; 90: 156–172.
117. Xia L, Wang XX, Hu XS, et al. Resveratrol reduces endothelial progenitor cells
senescence through augmentation of telomerase activity by Akt-dependent
mechanisms. Br J Pharmacol 2008; 155: 387–394.
118. Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association
of marine omega-3 fatty acid levels with telomeric aging in patients with coronary
heart disease. J Am Med Assoc 2010; 303(3): 250–257.
119. Bode-Boger SM, Martens-Lobenhoffer J, Tager M, Schroder H, Scalera F. Aspirin
reduces endothelial cell senescence. Biochem Biophys Res Commun 2005; 334:
1226–1232.
120. Donnini S, Terzuoli E, Ziche M, Morbidelli L. Sulfhydryl angiotensinconverting
enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase,
fibroblast growth factor-2, and telomerase crosstalk. J Pharmacol Exp Ther 2010
332; 3: 776–784.
121. Spyridopoulos I, Haendeler J, Urbich C, et al . Statins enhance migratory capacity
by upregulation of the telomere repeat-binding factor TRF2 in endothelial
progenitor cells. Circulation 2004; 110: 3136–3142.
122. Satoh M, Minami Y, Takahashi Y, et al. Effect of intensive lipidlowering therapy
on telomere erosion in endothelial progenitor cells obtained from patients with
coronary artery disease. Clin Sci 2009; 116: 827–835.
123. Saliques S, Teyssier J-R, Vergely C, Lorgis L, et al. Circulating leucocyte telomere
length and oxidative stress : A new target for statin therapy. Atherosclerosis
2011, doi:10.1016/j.atherosclerosis.2011.09.011.
124. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res
2002; 30: e47.
125. Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, Harley CB, Aviv A.
Measurement of telomere length by the Southern blot analysis of terminal
restriction fragment lengths. Nature Protocols 2010; 5(9): 1596–1607.
126. Huzen J, van Veldhuisen DJ, van Gilst WH, van der Harst P. Telomeres and
biological ageing in cardiovascular disease. Ned Tijdschr Geneeskd 2008; 152:
1265–1270.
Blood glucose levels during acute illness can help predict future
diabetes risk
Blood glucose levels measured in hospitalised patients during
acute illness predicted the risk of developing type 2 diabetes in
the following three years, according to a study published in PLos
Medicine in August 2014.
Scottish researchers measured the blood glucose levels of 86
634 patients, aged 40 years or older, admitted for an acute illness
between 2004 and 2008. Patients were followed up to December
2011 to determine their type 2 diabetes risk.
The researchers reported that type 2 diabetes risk for patients with
a glucose level of less than 90 mg/dl (5 mmol/l) was 1% and the risk
increased to approximately 15% among those with a glucose level of
270 mg/dl (15 mmol/l) or more. Plus, the risk of developing diabetes
increased with increasing blood glucose levels during admission.
Based on the findings, the researchers developed a risk
calculator that uses the patient’s age, gender and admission blood
glucose level to predict
risk of developing diabetes
over three years follow-
ing hospital admission.
However, the risk calculator
has not yet been tested in
non-white populations
or populations outside of
Scotland.
The researchers said
in a press release, ‘These
findings can be used to
inform individual patients
of their long-term risk of
type 2 diabetes and to
offer lifestyle advice as
appropriate.’
C A R V E D I L O L 6,25 mg 12,5 mg 25 mg
RESTORE
cardiac function
Carvetrend 6,25 mg.Each tablet contains 6,25 mg carvedilol. Reg. No.: RSA S3 37/7.1.3/0276 NAM NS2
08/7.1.3/0105 BOT S2 BOT1101790. Carvetrend 12,5 mg. Each tablet contains 12,5 mg carvedilol. Reg. No.:
RSA S3 37/7.1.3/0277 NAM NS2 08/7.1.3/0104 BOT S2 BOT1101791. Carvetrend 25 mg. Each tablet contains
25 mg carvedilol. Reg. No.: RSA S3 37/7.1.3/0278 NAM NS2 08/7.1.3/0103 BOT S2 BOT1101792. For full
prescribing information, refer to the package insert approved by the Medicines Control Council, 16 September
2004. CDD123/07/2015.
ß
CUSTOMER CARE LINE 0860 PHARMA (742 762)
A Lupin Group Company
References
16790&catid=1&Itemid=17.